<DOC>
	<DOCNO>NCT03104166</DOCNO>
	<brief_summary>50 patient randomize treated MCO highflux dialysis six month ( 24 week ) run-in phase 4 week Highflux treatment . Serum sample draw baseline , 4 , 8 24 week . Later , calcifiying vascular smooth muscle cell incubate serum sample calcification assess Alkaline phosphatase Alizarin staining . Primary endpoint : In vitro Calcification coronary vascular smooth muscle cell ( Alkaline Phosphatase/ WST8 ) six month Calcifiying vascular smooth muscle cell incubate serum sample obtain six month MCO/HF dialysis calcification assess Alkaline phosphatase WST8 . Secondary Endpoints : Aortic Pulse wave velocity 6 month Calcification propensity 6 month Physical activity level 6 month Cell culture : Incubation VSMC serum sample obtain 6 month - Alizarin staining/WST-8 - Measurement calcification inhibitor Osteopontin Matrix Gla Protein Supernatants - Apoptosis The treatment regimen patient alter , hence blood flow , dialysate flow well dialysis time remain constant .</brief_summary>
	<brief_title>Modulation Vascular Calcification Chronic Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<criteria>Age 18 year old Chronic dialysis patient least 3 month Serum albumin &lt; 32g/L last routine albumin measurement Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>